一体式覆膜支架用于腹主动脉瘤修复的安全性评价:系统综述与Meta分析
该系统综述与Meta分析共纳入14项研究(12项观察性研究、2项随机对照试验),Meta分析合并10项研究共12690例患者,评估一体式覆膜支架(AFX/AFX2)修复腹主动脉瘤的安全性;II型内漏发生率最高为12%(95%CI 4-20%),全因死亡率21%(95%CI 4-38%),技术成功率100%(95%CI 98-100%),作者认为该支架安全微创但需密切随访。
要点
- II型内漏发生率最高,为12%(95%CI 4-20%),III型内漏为3%(95%CI 1-5%),I型内漏为1%(95%CI 0-2%)。
- 全因死亡率为21%(95%CI 4-38%),动脉瘤相关死亡率为2%(95%CI 0-7%),动脉瘤破裂为6%(95%CI 2-11%)。
- 技术成功率为100%(95%CI 98-100%),肢体闭塞为1%(95%CI 0-1%),支架移植物移位为1%(95%CI 0-2%)。
核心结论
- 一体式覆膜支架是修复腹主动脉瘤安全且微创的方法,但潜在并发症要求介入后密切随访患者。
研究设计与样本
- 系统综述与Meta分析,检索Cochrane Library、Scopus、Web of Science和PubMed,纳入2014年至2023年间评估一体式覆膜支架修复腹主动脉瘤的研究。
- 系统综述纳入14项研究,包括12项观察性研究和2项随机对照试验;Meta分析纳入10项报告所测结局的研究共12690例患者,排除4项未报告的研究。
主要发现
- II型内漏发生率最高为12%(95%CI 4-20%),III型内漏为3%(95%CI 1-5%),I型内漏为1%(95%CI 0-2%)。
- 按随访时长亚组分析,II型内漏发生率在随访1至2年后高于随访3至4年后。
- 动脉瘤相关死亡率为2%(95%CI 0-7%),肢体闭塞为1%(95%CI 0-1%),支架移植物移位为1%(95%CI 0-2%)。
- 动脉瘤破裂为6%(95%CI 2-11%),入路部位问题为7%(95%CI 2-13%),瘤囊增长为2%(95%CI 0-4%)。
- 全因死亡率为21%(95%CI 4-38%),技术成功率为100%(95%CI 98-100%)。
临床怎么用
- 作者认为一体式覆膜支架是修复腹主动脉瘤安全且微创的方法,但潜在并发症要求介入后密切随访患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The unibody bifurcated aortic endograft (AFX/AFX2) has emerged as a treatment option for abdominal aortic aneurysms (AAAs). This systematic review and meta-analysis aimed to evaluate the safety of the unibody endograft. METHODS: A literature search was conducted in Cochrane Library, Scopus, Web of Science, and PubMed. Studies assessing the unibody endograft for AAA repair between 2014 and 2023 were included. The defined primary outcomes were the incidences of type I, II, and III endoleaks. The secondary outcomes were access site problems, aneurysm-related mortality, aneurysm rupture, all-cause mortality, aneurysm sac growth, limb occlusion, stent graft migration, and technical success rate. RESULTS: Fourteen studies including 12 observational studies and 2 randomized controlled trials were included in the systematic review. The meta-analysis included 10 studies with 12,690 patients that reported the measured outcomes, and excluded 4 studies that did not. Type II endoleaks had the highest incidence of 12% (95% confidence interval [CI]: 4-20%), followed by type III endoleaks with an incidence of 3% (95% CI: 1-5%). The incidence of type I endoleaks was 1% (95% CI: 0-2%). A subgroup analysis by follow-up duration showed that type II endoleak incidence was higher after 1 to 2 years of follow-up than 3 to 4 years of follow-up. The incidence of aneurysmal mortality was 2% (95% CI: 0-7%), limb occlusion was 1% (95% CI: 0-1%), stent graft migration was 1% (95% CI: 0-2%), aneurysmal rupture was 6% (95% CI: 2-11%), access site problems were 7% (95% CI: 2-13%), aneurysm sac growth was 2% (95% CI: 0-4%), all-cause mortality was 21% (95% CI: 4-38%), and technical success rate was 100% (95% CI: 98-100%). CONCLUSIONS: The unibody endograft is a safe and minimally invasive approach for AAA repair. However, potential complications necessitate close patient follow-up after the intervention.
引用
- Essam S, Hussein M, Ahmed AM, et al. Safety Evaluation of Unibody Endografts for Abdominal Aortic Aneurysm Repair: A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2024. PMID: 38960091. doi:10.1016/j.avsg.2024.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。